Format

Send to

Choose Destination
J Clin Invest. 2010 Dec;120(12):4168-78. doi: 10.1172/JCI44423. Epub 2010 Dec 1.

Advances and challenges in malaria vaccine development.

Author information

1
Laboratory of Immunogenetics, National Institute of Allergy and Infectious Disease (NIAID), NIH, Rockville, Maryland, USA.

Abstract

Malaria caused by Plasmodium falciparum remains a major public health threat, especially among children and pregnant women in Africa. An effective malaria vaccine would be a valuable tool to reduce the disease burden and could contribute to elimination of malaria in some regions of the world. Current malaria vaccine candidates are directed against human and mosquito stages of the parasite life cycle, but thus far, relatively few proteins have been studied for potential vaccine development. The most advanced vaccine candidate, RTS,S, conferred partial protection against malaria in phase II clinical trials and is currently being evaluated in a phase III trial in Africa. New vaccine targets need to be identified to improve the chances of developing a highly effective malaria vaccine. A better understanding of the mechanisms of naturally acquired immunity to malaria may lead to insights for vaccine development.

PMID:
21123952
PMCID:
PMC2994342
DOI:
10.1172/JCI44423
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for American Society for Clinical Investigation Icon for PubMed Central
Loading ...
Support Center